Expression and cellular localization of metalloproteases ADAMs in high graded carotid artery lesions

References

• Chalela JA. Evaluating the carotid plaque: going beyond stenosis. Cerebrovasc Dis 2009;27:19–24.
   PubMed Web of Science ®Google Scholar
• Rerkasem K, Rothwell PM. Temporal trends in the risks of stroke and death due to endarterectomy for symptomatic carotid stenosis: an updated systematic review. Eur J Vasc Endovasc Surg 2009;37:504–11.
   Google Scholar
• Randomised trial of endarterectomy for recently symptomatic carotid stenosis: final results of the MRC European Carotid Surgery Trial (ECST). Lancet 1998;351:1379–87.
   PubMed Web of Science ®Google Scholar
• Hollander M, Hak AE, Koudstaal PJ, Bots ML, Grobbee DE, Hofman A, Witteman JC, Breteler MM. Comparison between measures of atherosclerosis and risk of stroke: the Rotterdam Study. Stroke 2003;34:2367–72.
   PubMed Web of Science ®Google Scholar
• Eckstein HH, Heider P, Wolf O, Barone M, Hanke M. Controversies in the treatment of carotid stenoses. Present state of research and evidence-based medicine. Chirurg 2004;75:672–80.
   Google Scholar
• Virmani R, Burke AP, Farb A, Kolodgie FD. Pathology of the vulnerable plaque. J Am Coll Cardiol 2006;47:C13–C18.
   PubMed Web of Science ®Google Scholar
• Dollery CM, Libby P. Atherosclerosis and proteinase activation. Cardiovasc Res 2006;69:625–35.
   PubMed Web of Science ®Google Scholar
• Newby AC. Dual role of matrix metalloproteinases (matrixins) in intimal thickening and atherosclerotic plaque rupture. Physiol Rev 2005;85:1–31.
   PubMed Web of Science ®Google Scholar
• Bäck M, Ketelhuth DF, Agewall S. Matrix metalloproteinases in atherothrombosis. Prog Cardiovasc Dis 2010;52: 410–28.
   PubMed Web of Science ®Google Scholar
• Halvorsen B, Otterdal K, Dahl TB, Skjelland M, Gullestad L, Øie E, Aukrust P. Atherosclerotic plaque stability – what determines the fate of a plaque?Prog Cardiovasc Dis. 2008;51:183–94.
   PubMed Web of Science ®Google Scholar
• Duffy MJ, McKiernan E, O'Donovan N, McGowan PM. The role of ADAMs in disease pathophysiology. Clin Chim Acta 2009;403:31–6.
   PubMed Web of Science ®Google Scholar
• Blobel CP. ADAMs: key components in EGFR signalling and development. Nature 2005;6:32–43.
   Google Scholar
• Seals DF, Courtneidge SA. The ADAMs family of metalloproteases: multidomain proteins with multiple functions. Genes Dev 2003;17:7–30.
   PubMed Web of Science ®Google Scholar
• Sahin U, Weskamp G, Kelly K, Zhou HM, Higashiyama S, Peschon J, Hartmann D, Saftig P, Blobel CP. Dictinct roles for ADAM 10 and ADAM 17 in ectodomain shedding of six EGFR ligands. J Cell Biol 2004;164:769–79.
   PubMed Web of Science ®Google Scholar
• van Goor H, Melenhorst WB, Turner AJ, Holgate ST. Adamalysins in biology and disease. J Pathol 2009;219:277–86.
   PubMed Web of Science ®Google Scholar
• Mochizuki S, Okada Y. ADAMs in cancer cell proliferation and progression. Cancer Sci 2007;98:621–8.
   PubMed Web of Science ®Google Scholar
• Millichip MI, Dallas DJ, Wu E, Dale S, McKie N. The metallo-disintegrin ADAM 10 from bovine kidney has type IV collagenase activity in vitro. Biochem Biophys Res Commun 1998;245:594–8.
   PubMed Web of Science ®Google Scholar
• Herren B, Raines EW, Ross R. Three putative integrin ligands identified in human aortic smooth muscle cells. Ann N Y Acad Sci 1997;811:498–505.
   Google Scholar
• Edwards DR, Handsley MM, Pennington CJ. The ADAM metalloproteinases. Mol Aspects Med 2008;29:258–89.
   PubMed Web of Science ®Google Scholar
• Murphy G. Regulation of the proteolytic disintegrin metalloproteinases, the ‘Sheddases’. Semin Cell Dev Biol 2009;20:138–45.
   PubMed Web of Science ®Google Scholar
• Stary HC. Natural history and histological classification of atherosclerotic lesions: an update. Arterioscler Thromb Vasc Biol 2000;20:1177–8.
   PubMed Web of Science ®Google Scholar
• World Medical Association. Declaration of Helsinki. Recommendations guiding physicians in biomedical research involving human subjects. Cardiovasc Res 1997;35:2–3.
   Google Scholar
• Virmani R, Burke AP, Farb A, Kolodgie, FD. Pathology of the vulnerable plaque. J Am Coll Cardiol 2006;47: C13–C18.
   PubMed Web of Science ®Google Scholar
• Redgrave JN, Gallagher PJ, Lovett JK, Rothwell PM. Critical cap thickness and rupture in symptomatic carotid plaques: the Oxford Plaque Study. Stroke 2008;39:1722–9.
   PubMed Web of Science ®Google Scholar
• Oksala N, Levula M, Airla N, Pelto-Huikko M, Ortiz RM, Järvinen O, Salenius JP, Ozsait B, Komurcu-Bayrak E, Erginel-Unaltuna N, Huovila AP, Kytömäki L, Soini JT, Kähönen M, Karhunen PJ, Laaksonen R, Lehtimäki T. ADAM-9, ADAM-15, and ADAM-17 are upregulated in macrophages in advanced human atherosclerotic plaques in aorta and carotid and femoral arteries-Tampere vascular study. Ann Med 2009;41:279–90.
   PubMed Web of Science ®Google Scholar
• Al-Fakhri N, Wilhelm J, Hahn M, Heidt M, Hehrlein FW, Endisch AM, Hupp T, Cherian SM, Bobryshev YV, Lord RS, Katz N. Increased expression of disintegrin-metalloproteinases ADAM-15 and ADAM-9 following upregulation of integrins alpha5beta1 and alphavbeta3 in atherosclerosis. J Cell Biochem 2003;89:808–23.
   PubMed Web of Science ®Google Scholar
• Holdt LM, Thiery J, Breslow JL, Teupser D. Increased ADAM17 mRNA expression and activity is associated with atherosclerosis resistance in LDL-receptor deficient mice. Arterioscler Thromb Vasc Biol 2008;28:1097–103.
   Google Scholar
• Ishikawa N, Daigo Y, Yasui W, Inai K, Nishimura H, Tsuchiya E, Kohno N, Nakamura Y. ADAM8 as a novel serological and histochemical marker for lung cancer. Clin Cancer Res 2004;10:8363–70.
   PubMed Web of Science ®Google Scholar
• Rocks N, Paulissen G, El Hour M, Quesada F, Crahay C, Gueders M, Foidart JM, Noel A, Cataldo D. Emerging roles of ADAM and ADAMTS metalloproteinases in cancer. Biochimie 2008;90:369–79.
   PubMed Web of Science ®Google Scholar
• Hinkle CL, Sunnarborg SW, Loiselle D, Parker CE, Stevenson M, Russell WE, Lee DC. Selective roles for tumor necrosis factor alpha-converting enzyme/ADAM17 in the shedding of the epidermal growth factor receptor ligand family: the juxtamembrane stalk determines cleavage efficiency. J Biol Chem 2004;279:24179–88.
   PubMed Web of Science ®Google Scholar
• Heo SH, Cho CH, Kim HO, Jo YH, Yoon KS, Lee JH, Park JC, Park KC, Ahn TB, Chung KC, Yoon SS, Chang DI. Plaque rupture is a determinant of vascular events in carotid artery atherosclerotic disease: involvement of matrix metalloproteinases 2 and 9. J Clin Neurol 2011;7:69–76.
   PubMedGoogle Scholar
• Satoh H, Nakamura M, Satoh M, Nakajima T, Izumoto H, Maesawa C, Kawazoe K, Masuda T, Hiramori K. Expression and localization of tumour necrosis factor-alpha and its converting enzyme in human abdominal aortic aneurysm. Clin Sci (Lond) 2004;106:301–6.
   Google Scholar
• Herren B, Raines E, Ross R. Expression of a disintegrin-like protein in cultured human vascular cells and in vivo. FASEB J 1997;11:173–80.
   PubMed Web of Science ®Google Scholar
• Mizuno Y, Jacob RF, Mason RP. Inflammation and the development of atherosclerosis. J Atheroscler Thromb 2011;18:351–8.
   Google Scholar
• Di Stefano R, Felice F, Balbarini A. Angiogenesis as risk factor for plaque vulnerability. Curr Pharm Des 2009;15: 1095–106.
   PubMed Web of Science ®Google Scholar
• Brew K, Dinakarpandian D, Nagase H. Tissue inhibitors of metalloproteinases: evolution, structure and function. Biochim Biophys Acta 2000;1477:267–83.
   PubMed Web of Science ®Google Scholar
• Hermus L, Lefrandt JD, Tio RA, Breek JC, Zeebregts CJ. Carotid plaque formation and serum biomarkers. Atherosclerosis 2010;213:21–9.
   PubMedGoogle Scholar
• Wang TJ, Gona P, Larson MG, Tofler GH, Levy D, Newton-Cheh C, Jacques PF, Rifai N, Benjamin EJ, D'Agostino RB, Vasan RS. Multiple biomarkers for the prediction of first major cardiovascular events and death. New Eng J Med 2008;355:2631–9.
   Google Scholar
• Pelisek J, Rudelius M, Zepper P, Poppert H, Reeps C, Schuster T, Eckstein HH. Multiple biological predictors for vulnerable carotid lesions. Cerebrovasc Dis 2009;28:601–10.
   Google Scholar
• Jacobsen J, Visse R, Sørensen HP, Enghild JJ, Brew K, Wewer UM, Nagase H. Catalytic properties of ADAM12 and its domain deletion mutants. Biochemistry 2008;47: 537–47.
   Google Scholar
• Maretzky T, Yang G, Ouerfelli O, Overall CM, Worpenberg S, Hassiepen U, Eder J, Blobel CP. Characterization of the catalytic activity of the membrane-anchored metalloproteinase ADAM15 in cell-based assays. Biochem J 2009;420:105–13.
   Google Scholar
• Amour A, Knight CG, English WR, Webster A, Slocombe PM, Knäuper V, Docherty AJ, Becherer JD, Blobel CP, Murphy G. The enzymatic activity of ADAM8 and ADAM9 is not regulated by TIMPs. FEBS Lett 2002;524:154–8.
   PubMed Web of Science ®Google Scholar
• Turu MM, Krupinski J, Catena E, Rosell A, Montaner J, Alvarez-Sabin J, Cairols M, Badimon L. Intraplaque MMP-8 levels are increased in asymptomatic patients with carotid plaque progression on ultrasound. Atherosclerosis 2006;187:161–9.
   PubMedGoogle Scholar
• Bicknell CD, Peck D, Lau NM, Alkhamesi NA, Cowling MG, Clark MW, Jenkins MP, Wolfe JH, Darzi AW, Cheshire NJ. The relationship between plasma MMP-1, -7, -8 and -13 levels and embolic potential during carotid endoluminal intervention. EJVES 2004;28:500–7.
   Google Scholar
• Sapienza P, di Marzo L, Borrelli V, Sterpetti AV, Mingoli A, Piagnerelli R, Cavallaro A. Basic fibroblast growth factor mediates carotid plaque instability through metalloproteinase-2 and -9 expression. EJVES 2004;28:89–97.
   Google Scholar